USPTO serial 97602817
RAPID
Reviewed by CopyMark Law Group
Status 601
- Filing date
- Status date
- Registration date
- —
- Examiner
- TATE-NAGHI, JACQUELINE P
- Law office
- TMO LAW OFFICE 120 - EXAMINING ATTORNEY ASSIGNED
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with RAPID?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leesa N. Weiss
Leesa N. Weiss Edell, Shapiro & Finnan, LLC9801 Washingtonian Blvd., Suite 750Gaithersburg, MD 20878UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | diagnostic reagents for clinical and medical laboratory use; diagnostic kits comprising reagents for testing bacteria sensitivity | ACTIVE | — |
| 005 | human, animal, plant and microorganism biological preparations for use in drug development, disease modeling and personalized medicine to prevent or treat bacterial infectious diseases; bactericides, namely, biological preparations to treat bacterial infections and bacterial contamination in the fields of medicine, farming, and food preparation; bactericides, namely, biological preparations to treat bacterial contamination in the industrial and food preparation fields; diagnostic kits comprised of medical diagnostic reagents for testing bacteria sensitivity | ACTIVE | — |
| 009 | computer software system for identifying precision therapy for treatment of bacterial infections | ACTIVE | — |
| 040 | custom manufacture of bacteriophage therapeutics | ACTIVE | — |
| 042 | research and development in the fields of personalized medicine and diagnostics; data mining of healthcare and genetic information in the field of precision medicine and personalized medicine; scientific study and research in the fields of biochemistry, disease, personalized medicine, personalized therapeutics, and/or pharmaceuticals; clinical and medical laboratory testing services for medical research purposes in the fields of disease diagnostics and personalized medicine; pharmaceutical drug research and development; custom assay development; pharmaceutical drug discovery and development services; providing laboratory research services in the field of medical diagnostics and personalized medicine; medical research services; biotechnology research; providing medical and scientific research information in the field of clinical trials; research and development of vaccines and therapeutics; non-downloadable computer software application in the field of personalized medicine to provide medical and diagnostic services involving bacterial infections; providing medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of bacterial infections and the analysis, evaluation and reporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; laboratory research in the field of genomic sequencing; research and development in the pharmaceutical and biotechnology fields; research development, engineering and testing services in the fields of bacteria and viruses; laboratory research in the field of infectious diseases; medical and scientific research in the field of immunotherapy; medical laboratory services; microbiological laboratory testing of bacteria for research purposes and technical consultation thereto; scientific and medical research, in particular, design and development of diagnostic assays | ACTIVE | — |
| 044 | medical testing for diagnostic or treatment purposes in the field of personalized medicine; health care services, namely, providing a database in the field of personalized medicine and featuring inputting and collection of data and information all for treatment and diagnostic purposes; clinical and medical laboratory testing services for diagnostic purposes in the fields of disease diagnostics and personalized medicine; providing medical diagnostic assays and diagnostic and prognostic testing for treatment purposes of bacteria infections and the analysis, evaluation, and reporting of those test results to help healthcare professionals determine a patient's clinical diagnosis, the effectiveness of patient treatments, and to revise future treatments accordingly; medical services; consulting services in the field of medical diagnostic and prognostic testing; medical analysis services for diagnostic and prognostic testing and treatment purposes; providing medical diagnostic and prognostic testing services; medical analysis services relating to the diagnosis and treatment of a person; microbiological laboratory testing of bacteria for diagnostic and medical purposes, and technical consultation thereto; medical testing and diagnostic services for diagnostic or treatment purposes, in particular performing tests using diagnostic assays | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Adaptive Phage Therapeutics, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named RAPID
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 15, 2023 | MAB1 | ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT | — |
| Jun 15, 2023 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Jun 14, 2023 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Apr 4, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 4, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 4, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 4, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 4, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 15, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 15, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 15, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 6, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 11, 2022 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Oct 9, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 26, 2022 | NWAP | NEW APPLICATION ENTERED | — |